Get the Stockscreener App
1.02
7.27%
-0.08
After Hours:
1.04
0.02
+1.96%
Sutro Biopharma Inc stock is traded at $1.02, with a volume of 549.54K.
It is down -7.27% in the last 24 hours and up +12.27% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$1.10
Open:
$1.09
24h Volume:
549.54K
Relative Volume:
0.66
Market Cap:
$86.47M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-0.573
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
-7.69%
1M Performance:
+12.27%
6M Performance:
-7.27%
1Y Performance:
-72.36%
1-Day Range:
$1.02
$1.105
1-Week Range:
$1.01
$1.205
52-Week Range:
$0.5231
$4.60
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
1.02 | 93.25M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Can technical indicators confirm Sutro Biopharma Inc.’s reversalMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
Volatility clustering patterns for Sutro Biopharma Inc.Market Activity Report & Technical Pattern Based Signals - newser.com
Applying big data sentiment scoring on Sutro Biopharma Inc.Oil Prices & Reliable Entry Point Trade Alerts - newser.com
Statistical indicators supporting Sutro Biopharma Inc.’s strengthChart Signals & Safe Capital Investment Plans - newser.com
Published on: 2025-11-04 05:15:30 - newser.com
Can Sutro Biopharma Inc. stock sustain revenue growth2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
Why Sutro Biopharma Inc. stock is considered a top pickJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
What earnings margins imply for Sutro Biopharma Inc. (S09) stockWeekly Trade Summary & Growth Oriented Trading Recommendations - newser.com
Can Sutro Biopharma Inc. (S09) stock deliver strong annual returnsTrade Signal Summary & Daily Profit Maximizing Tips - newser.com
Can Sutro Biopharma Inc. recover in the next quarter2025 Analyst Calls & Consistent Growth Equity Picks - newser.com
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - The Manila Times
Sutro Biopharma, Inc. to Present Innovative Preclinical Data at World ADC Conference 2025 - Quiver Quantitative
Sutro (NASDAQ: STRO) to present preclinical data on dual-payload ADCs at World ADC - Stock Titan
What candlestick patterns are forming on Sutro Biopharma Inc.Jobs Report & High Return Trade Guides - newser.com
Analyzing Sutro Biopharma Inc. with risk reward ratio chartsMarket Performance Summary & Long-Term Capital Growth Strategies - newser.com
Is it too late to sell Sutro Biopharma Inc.Weekly Trading Summary & Real-Time Volume Analysis - newser.com
Published on: 2025-11-02 22:36:42 - newser.com
Is Sutro Biopharma Inc. stock a safe haven assetDollar Strength & Daily Profit Focused Screening - newser.com
Is Sutro Biopharma Inc. stock a buy on dipsDividend Hike & AI Enhanced Trade Execution Alerts - newser.com
Applying Wyckoff theory to Sutro Biopharma Inc. stockDividend Hike & Smart Money Movement Alerts - newser.com
Published on: 2025-11-01 09:13:17 - newser.com
How to monitor Sutro Biopharma Inc. with trend dashboards2025 Valuation Update & Precise Buy Zone Tips - newser.com
How buybacks impact Sutro Biopharma Inc. stock valuePortfolio Update Report & Technical Confirmation Alerts - newser.com
Does Sutro Biopharma Inc. show high probability of rebound2025 Trade Ideas & Reliable Intraday Trade Alerts - newser.com
Identifying reversal signals in Sutro Biopharma Inc.Market Performance Recap & Real-Time Sentiment Analysis - newser.com
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):